172 related articles for article (PubMed ID: 35294623)
21. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Blin P; Dureau-Pournin C; Cottin Y; Bénichou J; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
Br J Clin Pharmacol; 2019 Feb; 85(2):432-441. PubMed ID: 30423205
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
[TBL] [Abstract][Full Text] [Related]
24. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
[TBL] [Abstract][Full Text] [Related]
25. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
[TBL] [Abstract][Full Text] [Related]
26. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
[TBL] [Abstract][Full Text] [Related]
27. Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Gaubert M; Resseguier N; Laine M; Bonello L; Camoin-Jau L; Paganelli F
J Thromb Haemost; 2018 Mar; 16(3):465-473. PubMed ID: 29274198
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Russo V; Rago A; Proietti R; Attena E; Rainone C; Crisci M; Papa AA; Calabrò P; D'Onofrio A; Golino P; Nigro G
Biomed Res Int; 2019; 2019():5473240. PubMed ID: 30895193
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
30. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
Grosse GM; Hüsing A; Stang A; Kuklik N; Brinkmann M; Nabavi D; Sparenberg P; Weissenborn K; Gröschel K; Royl G; Poli S; Michalski D; Eschenfelder CC; Weimar C; Diener HC;
Int J Stroke; 2023 Dec; 18(10):1169-1177. PubMed ID: 37306492
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
32. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.
Liu X; Feng G; Marler SV; Huisman MV; Lip GYH; Ma C
Thromb J; 2023 Aug; 21(1):83. PubMed ID: 37528405
[TBL] [Abstract][Full Text] [Related]
33. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
[TBL] [Abstract][Full Text] [Related]
34. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
[TBL] [Abstract][Full Text] [Related]
35. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
[TBL] [Abstract][Full Text] [Related]
36. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
[TBL] [Abstract][Full Text] [Related]
37. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
38. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D
Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915
[TBL] [Abstract][Full Text] [Related]
40. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]